Literature DB >> 15193254

Lost in translation: dysregulation of cap-dependent translation and cancer.

Mary-Ann Bjornsti1, Peter J Houghton.   

Abstract

Activation of the phosphatidylinositol 3' kinase-Akt pathway has long been associated with malignant transformation and antiapoptotic signaling. Mutations downstream of Akt that activate the TOR kinase are found in tumor-prone syndromes, while overexpression of translation initiation complex components, such as eIF4E, occurs frequently in human cancer. However, direct roles for TOR signaling or eIF4E overexpression, in the genesis of cancer, have been lacking. Recent papers, including one by in this issue of Cancer Cell, clearly establish that dysregulation of cap-dependent translation confers malignant characteristics and induces cancer by suppressing apoptosis, underscoring the potential of therapeutics that selectively target the Akt-TOR-eIF4E pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193254     DOI: 10.1016/j.ccr.2004.05.027

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  57 in total

1.  Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.

Authors:  Yikun Li; Ping Yue; Xingming Deng; Takeshi Ueda; Rikiro Fukunaga; Fadlo R Khuri; Shi-Yong Sun
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Authors:  Paige Yellen; Mahesh Saqcena; Darin Salloum; Jiangnan Feng; Angela Preda; Limei Xu; Vanessa Rodrik-Outmezguine; David A Foster
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 3.  Amino acid management in cancer.

Authors:  Zhi-Yang Tsun; Richard Possemato
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

Review 4.  Everolimus.

Authors:  Peter J Houghton
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

5.  Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein.

Authors:  Kwang-Jin Oh; Anna Kalinina; No-Hee Park; Srilata Bagchi
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation.

Authors:  Priam Villalonga; Silvia Fernández de Mattos; Anne J Ridley
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

7.  Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells.

Authors:  Mariko Tomita; Gregg L Semenza; Canine Michiels; Takehiro Matsuda; Jun-Nosuke Uchihara; Taeko Okudaira; Yuetsu Tanaka; Naoya Taira; Kazuiku Ohshiro; Naoki Mori
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

8.  Codon misreading tRNAs promote tumor growth in mice.

Authors:  Mafalda Santos; Patricia M Pereira; A Sofia Varanda; Joana Carvalho; Mafalda Azevedo; Denisa D Mateus; Nuno Mendes; Patricia Oliveira; Fábio Trindade; Marta Teixeira Pinto; Renata Bordeira-Carriço; Fátima Carneiro; Rui Vitorino; Carla Oliveira; Manuel A S Santos
Journal:  RNA Biol       Date:  2018-06-07       Impact factor: 4.652

9.  4E-BP1 is a target of Smad4 essential for TGFbeta-mediated inhibition of cell proliferation.

Authors:  Rania Azar; Amandine Alard; Christiane Susini; Corinne Bousquet; Stéphane Pyronnet
Journal:  EMBO J       Date:  2009-10-15       Impact factor: 11.598

10.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

Authors:  Liang Cao; Yunkai Yu; Isaac Darko; Duane Currier; Linnia H Mayeenuddin; Xiaolin Wan; Chand Khanna; Lee J Helman
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.